• Analysis of non-life insurers' Solvency and Financial Condition Reports: European non-life insurers year-end 2017

  By Derek Newton, Marc Smillie, Flavien Thery | 25 March 2019

  The analyses underlying this report focus on the quantitative information contained in the Quantitative Reporting Templates with the Solvency and Financial Condition Reports and draw conclusions about the balance sheets and risk exposures of European non-life insurers.

• Role of data in transforming UK private medical insurance analytics

  By Joanne Buckle, Natasha Singhal | 25 March 2019

  As insurers and providers delve into advanced analytics, each hopes to achieve more precise decisions for applications ranging from risk and finance to making individual patient care decisions.

• The Withdrawal Delay Cohort under VM-21/AG-43: The case for random sampling

  By Benjamin Buttin, Matthias Kullowatz, Zi Xiang Low, Zohair Motiwalla | 25 March 2019

  The VM-21 Standard Projection is essentially a complete overhaul of the existing Actuarial Guideline 43 Standard Scenario framework.

• Analysis of non-life insurers' Solvency and Financial Condition Reports: United Kingdom and Gibraltar non-life insurers year-end 2017

  By Derek Newton, Flavien Thery, Marc Smillie | 25 March 2019

  This report summarises the year-end 2017 Solvency and Financial Condition Reports as they relate to non-life insurers regulated in the UK and Gibraltar, and sets out the results of the analyses of the reports.

• Microinsurance and rural development in China: A Q&A with Associate Professor Yi Yao (Kitty) of Peking University

  By Queenie Chow, Mariah Mateo Sarpong | 25 March 2019

  What is the microinsurance market like in China and how is it defined?

• Amendments to IFRS 17 from March 2019 IASB Meeting

  By Andrew Gilchrist, Laura Hobern, Andrew Kay, Rik van Beers, Thomas Bulpitt | 25 March 2019

  Milliman consultants have produced a summary of the March IASB meeting and the tentative amendments approved by the Board.

• HHS’s proposed modification of pharmacy rebate safe harbors

  By Christine M. Mytelka | 22 March 2019

  This paper focuses on potential implications of the proposed modifications to safe harbor regulations for state Medicaid agencies and the Children’s Health Insurance Program.

• Milliman Combination Product Experience Study

  By Carl A. Friedrich, Allen J. Schmitz | 21 March 2019

  Milliman announces the results of the first-of-its-kind, industry-wide study that examines insurers’ experience with combination products-- those that couple life or annuity policies with Long-Term Care or Chronic Illness riders.

• Analysis of Dutch insurers’ Solvency and Financial Condition Reports: Year-end 2017

  By Peter Franken, Kamiel van Langen, Wouter van Goudoever, Rens IJsendijk | 21 March 2019

  This report provides a summary of the key solvency information of the main life and non-life insurance entities in the Netherlands based on Solvency and Financial Condition Reports as per year-end 2017.

• Putting a price tag on health

  By Stoddard Davenport | 20 March 2019

  Value in healthcare is about more than just reducing costs—improving health outcomes is a key part of the cost/value equation.

See More Articles